Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
:This is a an open-label, single-arm study to evaluate the efficacy and safety of zanubrutinib and G-CHOP in untreated Intermediate-high risk Follicular Lymphoma patients.
FL
DRUG: Zanubrutinib|DRUG: Obinutuzumab|DRUG: Prednisone|DRUG: Cyclophosphamide|DRUG: Vincristine|DRUG: Doxorubicin
CR (complete response) rate after induction (4 or 6 Cycles) by investigator (INV), Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria, From enrollment to the end of treatment at cycle 4 or 6 (each cycle is 28 days)
Objective Response rate after induction by investigator (INV), ORR is defined as the proportion of patients achieving complete response (CR) or partial response (PR), as determined by INV according to 2014 Lugano criteria, From enrollment to the end of end of treatment at cycle 4 or 6 (each cycle is 28 days)|Overall survival (OS), Overall survival (OS) is defined as the duration from the date of initiation of the first cycle of treatment to the date of death because of any cause, From the date of cycle 1, day 1 to the date of death regardless of cause, assessed up to 3 years|Progression free survival (PFS), -PFS defined as time from the date of enrollment to the date of first confirmed disease progression or death due to any cause, whichever occurs first, as determined by INV, From the date of cycle 1, day 1 to the date of death regardless of cause, assessed up to 3 years
:This is a an open-label, single-arm study to evaluate the efficacy and safety of zanubrutinib and G-CHOP in untreated Intermediate-high risk Follicular Lymphoma patients.